In the spotlight: Abolfazl Soltani’s Public PhD defense, Friday, Dec 11

In the spotlight

This coming Friday Abolfazl Soltani, one of our Mobilisers from EPFL, Switzerland, will have the public defense of his PhD thesis.  In his PhD work, Abolfazl has focused on accurate walking speed estimation and walking bout detection based on wrist-worn sensors. Although there are many different digital systems that can monitor gait in unsupervised free-living situations such as housekeeping, catching a bus, and shopping, they each have different advantages and disadvantages.   One such system, the Global Navigation Satellite System (GNSS), can measure real-world gait speed accurately, but…

New publication: A roadmap to inform development, validation and approval of digital mobility outcomes: the Mobilise-D approach

Publications

Well known biomarkers such as blood pressure, respiration, temperature, pulse, and pain are frequently used by physicians and other health professionals to describe a patient’s health and disease status. In addition to these ‘signs of life’, there is another important aspect of people’s health and disease status, namely their mobility – how well they walk. Loss of physical mobility, such as reduced walking speed, is a significant feature of many health…

EMA Public Support for Mobilise-D

Other

In the first year of Mobilise-D, we asked the European Medicines Agency (EMA) for qualification advice for Digital Mobility Outcomes (DMOs). EMA just published their letter of support that publicly endorses our initial stage in the wider objective of the Mobilise-D Consortium to pursue the qualification of Digital Mobility Outcomes (DMOs) as monitoring biomarkers of…

NIHR NEWS: Monitoring patients’ mobility continues despite new lockdown

Technical Validation Study

Monitoring patients’ mobility during the COVID19 pandemic could easily have been impossible due to lockdown and restrictions such as social distancing. However, this isn’t the case for the Mobilise-D technical validation study (TVS) where 120 participants with chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, congestive heart failure or hip fracture, along with healthy older adults, will be enrolled. Our test sites in Newcastle and Sheffield have found a way to work around the distancing restrictions to keep the study open, and confirmed that the technical validation…

[Publication] Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinson’s Patients Using Digital Mobility Outcomes

Publications

Today’s smartwatches and activity bracelets, like FitBit, Apple, and Samsung, have motion sensors that can measure your daily activity. These technologies can tell you how much or little active you are, for example by counting your daily number of steps, heart rate or track your movements with GPS. In both basic and clinical research, similar…

– I felt Mobilise-D!

Real World Stories

REAL WORLD STORIES – Episode 1 Mobility – how well people walk – is an important marker of health. With advanced age, as well as disease and injury, mobility challenges often become prominent. The COVID-19 breakout and the subsequent lockdowns all over the world put severe restrictions on everyone’s mobility. However, as it turns out,…

[VIDEO] Introducing the Mobilise-D Clinical Trials

Video4 Comments

One of the many impacts of the COVID-19 lockdown earlier this year, has been the severe restrictions on mobility of both patients and the public. Furthermore, the ability to assess patients’ mobility has suffered as well because of the barriers created between researchers and participants. Being able to remotely monitor patients’ mobility in their natural…